On February 1, 2022 Hubro Therapeutics reported that on 31 January the first dose of FMPV-1 was successfully administered to the first subject in our phase I study FMPV-1-01 in healthy volunteers (Press release, Hubro Therapeutics, FEB 1, 2022, View Source [SID1234607573]). In the study FMPV-1 is co-administered with adjuvant GM-CSF. The study will assess safety and immune response in up to 16 subjects. In a first cohort eight subjects will be enrolled and, depending on the results, a second cohort of another eight subjects given a higher dose of FMPV-1 will follow. It is aimed at completing enrolment and active treatment in the study within the next six months.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!